Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 75

1.

Restricted Delivery of Talazoparib Across the Blood-Brain Barrier Limits the Sensitizing Effects of PARP Inhibition on Temozolomide Therapy in Glioblastoma.

Kizilbash SH, Gupta SK, Chang K, Kawashima R, Parrish KE, Carlson BL, Bakken KK, Mladek AC, Schroeder MA, Decker PA, Kitange GJ, Shen Y, Feng Y, Protter AA, Elmquist WF, Sarkaria JN.

Mol Cancer Ther. 2017 Dec;16(12):2735-2746. doi: 10.1158/1535-7163.MCT-17-0365. Epub 2017 Sep 25.

PMID:
28947502
2.

Discovery of pyrazolopyrimidine derivatives as novel inhibitors of ataxia telangiectasia and rad3 related protein (ATR).

Ramachandran SA, Jadhavar PS, Singh MP, Sharma A, Bagle GN, Quinn KP, Wong PY, Protter AA, Rai R, Pham SM, Lindquist JN.

Bioorg Med Chem Lett. 2017 Feb 15;27(4):750-754. doi: 10.1016/j.bmcl.2017.01.045. Epub 2017 Jan 16.

PMID:
28131712
3.

Temozolomide analogs with improved brain/plasma ratios - Exploring the possibility of enhancing the therapeutic index of temozolomide.

Rai R, Banerjee M, Wong DH, McCullagh E, Gupta A, Tripathi S, Riquelme E, Jangir R, Yadav S, Raja M, Melkani P, Dixit V, Patil U, Shrivastava R, Middya S, Olivares F, Guerrero J, Surya A, Pham SM, Bernales S, Protter AA, Hung DT, Chakravarty S.

Bioorg Med Chem Lett. 2016 Oct 15;26(20):5103-5109. doi: 10.1016/j.bmcl.2016.08.064. Epub 2016 Aug 21.

PMID:
27614414
4.

Role of the androgen receptor in breast cancer and preclinical analysis of enzalutamide.

Cochrane DR, Bernales S, Jacobsen BM, Cittelly DM, Howe EN, D'Amato NC, Spoelstra NS, Edgerton SM, Jean A, Guerrero J, Gómez F, Medicherla S, Alfaro IE, McCullagh E, Jedlicka P, Torkko KC, Thor AD, Elias AD, Protter AA, Richer JK.

Breast Cancer Res. 2014 Jan 22;16(1):R7. doi: 10.1186/bcr3599.

5.

Enzalutamide, an androgen receptor signaling inhibitor, induces tumor regression in a mouse model of castration-resistant prostate cancer.

Guerrero J, Alfaro IE, Gómez F, Protter AA, Bernales S.

Prostate. 2013 Sep;73(12):1291-305. doi: 10.1002/pros.22674. Epub 2013 Jun 13.

PMID:
23765603
6.

Latrepirdine stimulates autophagy and reduces accumulation of α-synuclein in cells and in mouse brain.

Steele JW, Ju S, Lachenmayer ML, Liken J, Stock A, Kim SH, Delgado LM, Alfaro IE, Bernales S, Verdile G, Bharadwaj P, Gupta V, Barr R, Friss A, Dolios G, Wang R, Ringe D, Protter AA, Martins RN, Ehrlich ME, Yue Z, Petsko GA, Gandy S.

Mol Psychiatry. 2013 Aug;18(8):882-8. doi: 10.1038/mp.2012.115. Epub 2012 Aug 7.

7.

Latrepirdine improves cognition and arrests progression of neuropathology in an Alzheimer's mouse model.

Steele JW, Lachenmayer ML, Ju S, Stock A, Liken J, Kim SH, Delgado LM, Alfaro IE, Bernales S, Verdile G, Bharadwaj P, Gupta V, Barr R, Friss A, Dolios G, Wang R, Ringe D, Fraser P, Westaway D, St George-Hyslop PH, Szabo P, Relkin NR, Buxbaum JD, Glabe CG, Protter AA, Martins RN, Ehrlich ME, Petsko GA, Yue Z, Gandy S.

Mol Psychiatry. 2013 Aug;18(8):889-97. doi: 10.1038/mp.2012.106. Epub 2012 Jul 31.

8.

Cognition-enhancing properties of Dimebon in a rat novel object recognition task are unlikely to be associated with acetylcholinesterase inhibition or N-methyl-D-aspartate receptor antagonism.

Giorgetti M, Gibbons JA, Bernales S, Alfaro IE, Drieu La Rochelle C, Cremers T, Altar CA, Wronski R, Hutter-Paier B, Protter AA.

J Pharmacol Exp Ther. 2010 Jun;333(3):748-57. doi: 10.1124/jpet.109.164491. Epub 2010 Mar 1.

9.

Topical alpha-selective p38 MAP kinase inhibition reduces acute skin inflammation in guinea pig.

Medicherla S, Ma JY, Reddy M, Esikova I, Kerr I, Movius F, Higgins LS, Protter AA.

J Inflamm Res. 2010;3:9-16. Epub 2010 Feb 18.

10.

Clinical implications of defective B-type natriuretic peptide.

Menon SG, Mills RM, Schellenberger U, Saqhir S, Protter AA.

Clin Cardiol. 2009 Dec;32(12):E36-41. doi: 10.1002/clc.20480.

11.

Long-term effects of B-type natriuretic peptide infusion after acute myocardial infarction in a rat model.

George I, Xydas S, Klotz S, Hay I, Ng C, Chang J, Xu K, Li Z, Protter AA, Wu EX, Oz MC, Wang J.

J Cardiovasc Pharmacol. 2010 Jan;55(1):14-20. doi: 10.1097/FJC.0b013e3181c5e743.

12.

Detection of endogenous B-type natriuretic peptide at very low concentrations in patients with heart failure.

Niederkofler EE, Kiernan UA, O'Rear J, Menon S, Saghir S, Protter AA, Nelson RW, Schellenberger U.

Circ Heart Fail. 2008 Nov;1(4):258-64. doi: 10.1161/CIRCHEARTFAILURE.108.790774. Epub 2008 Oct 14.

13.

Prolonged effects of B-type natriuretic peptide infusion on cardiac remodeling after sustained myocardial injury.

George I, Morrow B, Xu K, Yi GH, Holmes J, Wu EX, Li Z, Protter AA, Oz MC, Wang J.

Am J Physiol Heart Circ Physiol. 2009 Aug;297(2):H708-17. doi: 10.1152/ajpheart.00661.2008. Epub 2009 Jun 12.

14.

p38alpha-selective MAP kinase inhibitor reduces tumor growth in mouse xenograft models of multiple myeloma.

Medicherla S, Reddy M, Ying J, Navas TA, Li L, Nguyen AN, Kerr I, Hanjarappa N, Protter AA, Higgins LS.

Anticancer Res. 2008 Nov-Dec;28(6A):3827-33.

15.

p38 MAPK inhibition reduces diabetes-induced impairment of wound healing.

Medicherla S, Wadsworth S, Cullen B, Silcock D, Ma JY, Mangadu R, Kerr I, Chakravarty S, Luedtke GL, Dugar S, Protter AA, Higgins LS.

Diabetes Metab Syndr Obes. 2009 Jun 23;2:91-100.

16.

Transforming growth factor-beta blockade down-regulates the renin-angiotensin system and modifies cardiac remodeling after myocardial infarction.

Ellmers LJ, Scott NJ, Medicherla S, Pilbrow AP, Bridgman PG, Yandle TG, Richards AM, Protter AA, Cameron VA.

Endocrinology. 2008 Nov;149(11):5828-34. doi: 10.1210/en.2008-0165. Epub 2008 Jul 24.

PMID:
18653707
17.

Role of p38 mitogen activated protein kinase in a model of osteosarcoma-induced pain.

Svensson CI, Medicherla S, Malkmus S, Jiang Y, Ma JY, Kerr I, Brainin-Mattos J, Powell HC, Luo ZD, Chakravarty S, Dugar S, Higgins LS, Protter AA, Yaksh TL.

Pharmacol Biochem Behav. 2008 Oct;90(4):664-75. doi: 10.1016/j.pbb.2008.05.016.

PMID:
18584857
18.

Antitumor activity of TGF-beta inhibitor is dependent on the microenvironment.

Medicherla S, Li L, Ma JY, Kapoun AM, Gaspar NJ, Liu YW, Mangadu R, O'Young G, Protter AA, Schreiner GF, Wong DH, Higgins LS.

Anticancer Res. 2007 Nov-Dec;27(6B):4149-57. Erratum in: Anticancer Res. 2008 Jan-Feb;28(1b):567, 4152-3.

19.

Pharmacological properties of SD-282 - an alpha-isoform selective inhibitor for p38 MAP kinase.

Koppelman B, Webb HK, Medicherla S, Almirez R, Feng Y, Chavez JC, Mao CP, Nguyen A, Liu YW, Kapoun AM, Muiru G, Huang YA, Dugar S, Mavunkel BJ, Lim DW, Chakravarty S, Luedtke G, Protter AA, Higgins LS.

Pharmacology. 2008;81(3):204-20. doi: 10.1159/000112865. Epub 2008 Jan 7.

PMID:
18176091
20.

Selective p38α mitogen-activated protein kinase inhibitor attenuates lung inflammation and fibrosis in IL-13 transgenic mouse model of asthma.

Ma JY, Medicherla S, Kerr I, Mangadu R, Protter AA, Higgins LS.

J Asthma Allergy. 2008 Nov 16;1:31-44.

21.

p38alpha-selective mitogen-activated protein kinase inhibitor SD-282 reduces inflammation in a subchronic model of tobacco smoke-induced airway inflammation.

Medicherla S, Fitzgerald MF, Spicer D, Woodman P, Ma JY, Kapoun AM, Chakravarty S, Dugar S, Protter AA, Higgins LS.

J Pharmacol Exp Ther. 2008 Mar;324(3):921-9. Epub 2007 Dec 4.

22.

Recombinant vascular endothelial growth factor 121 attenuates hypertension and improves kidney damage in a rat model of preeclampsia.

Li Z, Zhang Y, Ying Ma J, Kapoun AM, Shao Q, Kerr I, Lam A, O'Young G, Sannajust F, Stathis P, Schreiner G, Karumanchi SA, Protter AA, Pollitt NS.

Hypertension. 2007 Oct;50(4):686-92. Epub 2007 Aug 27.

23.

Inhibiting TGF-beta signaling restores immune surveillance in the SMA-560 glioma model.

Tran TT, Uhl M, Ma JY, Janssen L, Sriram V, Aulwurm S, Kerr I, Lam A, Webb HK, Kapoun AM, Kizer DE, McEnroe G, Hart B, Axon J, Murphy A, Chakravarty S, Dugar S, Protter AA, Higgins LS, Wick W, Weller M, Wong DH.

Neuro Oncol. 2007 Jul;9(3):259-70. Epub 2007 May 23. Erratum in: Neuro Oncol. 2007 Oct;9(4):465.

24.

Inhibition of p38alpha mitogen-activated protein kinase prevents the development of osteolytic bone disease, reduces tumor burden, and increases survival in murine models of multiple myeloma.

Vanderkerken K, Medicherla S, Coulton L, De Raeve H, Willems A, Lawson M, Van Camp B, Protter AA, Higgins LS, Menu E, Croucher PI.

Cancer Res. 2007 May 15;67(10):4572-7. Epub 2007 May 10.

25.

B-Type natriuretic peptide inhibited angiotensin II-stimulated cholesterol biosynthesis, cholesterol transfer, and steroidogenesis in primary human adrenocortical cells.

Liang F, Kapoun AM, Lam A, Damm DL, Quan D, O'Connell M, Protter AA.

Endocrinology. 2007 Aug;148(8):3722-9. Epub 2007 May 3.

PMID:
17478552
26.

Evidence for functional heterogeneity of circulating B-type natriuretic peptide.

Liang F, O'Rear J, Schellenberger U, Tai L, Lasecki M, Schreiner GF, Apple FS, Maisel AS, Pollitt NS, Protter AA.

J Am Coll Cardiol. 2007 Mar 13;49(10):1071-8. Epub 2007 Feb 26.

27.

A p38alpha selective mitogen-activated protein kinase inhibitor prevents periodontal bone loss.

Kirkwood KL, Li F, Rogers JE, Otremba J, Coatney DD, Kreider JM, D'Silva NJ, Chakravarty S, Dugar S, Higgins LS, Protter AA, Medicherla S.

J Pharmacol Exp Ther. 2007 Jan;320(1):56-63. Epub 2006 Oct 13.

28.

Effect of transforming growth factor-beta receptor I kinase inhibitor 2,4-disubstituted pteridine (SD-208) in chronic allergic airway inflammation and remodeling.

Leung SY, Niimi A, Noble A, Oates T, Williams AS, Medicherla S, Protter AA, Chung KF.

J Pharmacol Exp Ther. 2006 Nov;319(2):586-94. Epub 2006 Aug 3.

29.

Selective inhibition of p38alpha MAPK improves cardiac function and reduces myocardial apoptosis in rat model of myocardial injury.

Li Z, Ma JY, Kerr I, Chakravarty S, Dugar S, Schreiner G, Protter AA.

Am J Physiol Heart Circ Physiol. 2006 Oct;291(4):H1972-7. Epub 2006 Jun 2.

30.

The precursor to B-type natriuretic peptide is an O-linked glycoprotein.

Schellenberger U, O'Rear J, Guzzetta A, Jue RA, Protter AA, Pollitt NS.

Arch Biochem Biophys. 2006 Jul 15;451(2):160-6. Epub 2006 Apr 19.

PMID:
16750161
31.

Transforming growth factor-beta receptor type 1 (TGFbetaRI) kinase activity but not p38 activation is required for TGFbetaRI-induced myofibroblast differentiation and profibrotic gene expression.

Kapoun AM, Gaspar NJ, Wang Y, Damm D, Liu YW, O'young G, Quon D, Lam A, Munson K, Tran TT, Ma JY, Murphy A, Dugar S, Chakravarty S, Protter AA, Wen FQ, Liu X, Rennard SI, Higgins LS.

Mol Pharmacol. 2006 Aug;70(2):518-31. Epub 2006 May 17.

32.

Inhibition of p38alpha MAPK enhances proteasome inhibitor-induced apoptosis of myeloma cells by modulating Hsp27, Bcl-X(L), Mcl-1 and p53 levels in vitro and inhibits tumor growth in vivo.

Navas TA, Nguyen AN, Hideshima T, Reddy M, Ma JY, Haghnazari E, Henson M, Stebbins EG, Kerr I, O'Young G, Kapoun AM, Chakravarty S, Mavunkel B, Perumattam J, Luedtke G, Dugar S, Medicherla S, Protter AA, Schreiner GF, Anderson KC, Higgins LS.

Leukemia. 2006 Jun;20(6):1017-27.

PMID:
16617327
33.

Preventive and therapeutic potential of p38 alpha-selective mitogen-activated protein kinase inhibitor in nonobese diabetic mice with type 1 diabetes.

Medicherla S, Protter AA, Ma JY, Mangadu R, Almirez R, Koppelman B, Kerr I, Navas TA, Movius F, Reddy M, Liu YW, Luedtke G, Perumattam J, Mavunkel B, Dugar S, Schreiner GF.

J Pharmacol Exp Ther. 2006 Jul;318(1):99-107. Epub 2006 Apr 7.

34.

A selective p38 alpha mitogen-activated protein kinase inhibitor reverses cartilage and bone destruction in mice with collagen-induced arthritis.

Medicherla S, Ma JY, Mangadu R, Jiang Y, Zhao JJ, Almirez R, Kerr I, Stebbins EG, O'Young G, Kapoun AM, Luedtke G, Chakravarty S, Dugar S, Genant HK, Protter AA.

J Pharmacol Exp Ther. 2006 Jul;318(1):132-41. Epub 2006 Apr 5.

35.

Inhibition of p38 mitogen-activated protein kinase protects human islets from cryoinjury and improves the yield, viability, and quality of frozen-thawed islets.

Omori K, Valiente L, Orr C, Rawson J, Ferreri K, Todorov I, Medicherla S, Protter AA, Schreiner GF, Riggs AD, Kandeel F, Mullen Y.

Transplant Proc. 2005 Oct;37(8):3422-3.

PMID:
16298615
36.

p38 Inhibition attenuates the pro-inflammatory response to C-reactive protein by human peripheral blood mononuclear cells.

Lim MY, Wang H, Kapoun AM, O'connell M, O'Young G, Brauer HA, Luedtke GR, Chakravarty S, Dugar S, Schreiner GS, Protter AA, Higgins LS.

J Mol Cell Cardiol. 2004 Dec;37(6):1111-4.

PMID:
15572041
37.

Progressive transforming growth factor beta1-induced lung fibrosis is blocked by an orally active ALK5 kinase inhibitor.

Bonniaud P, Margetts PJ, Kolb M, Schroeder JA, Kapoun AM, Damm D, Murphy A, Chakravarty S, Dugar S, Higgins L, Protter AA, Gauldie J.

Am J Respir Crit Care Med. 2005 Apr 15;171(8):889-98. Epub 2004 Nov 24.

PMID:
15563636
38.

p38 alpha mitogen-activated protein kinase inhibition improves cardiac function and reduces myocardial damage in isoproterenol-induced acute myocardial injury in rats.

Li Z, Tran TT, Ma JY, O'Young G, Kapoun AM, Chakravarty S, Dugar S, Schreiner G, Protter AA.

J Cardiovasc Pharmacol. 2004 Oct;44(4):486-92.

PMID:
15454858
39.

Peripheral and central p38 MAPK mediates capsaicin-induced hyperalgesia.

Sweitzer SM, Peters MC, Ma JY, Kerr I, Mangadu R, Chakravarty S, Dugar S, Medicherla S, Protter AA, Yeomans DC.

Pain. 2004 Oct;111(3):278-85.

PMID:
15363871
40.

Antinociceptive action of a p38alpha MAPK inhibitor, SD-282, in a diabetic neuropathy model.

Sweitzer SM, Medicherla S, Almirez R, Dugar S, Chakravarty S, Shumilla JA, Yeomans DC, Protter AA.

Pain. 2004 Jun;109(3):409-19.

PMID:
15157702
41.

B-type natriuretic peptide exerts broad functional opposition to transforming growth factor-beta in primary human cardiac fibroblasts: fibrosis, myofibroblast conversion, proliferation, and inflammation.

Kapoun AM, Liang F, O'Young G, Damm DL, Quon D, White RT, Munson K, Lam A, Schreiner GF, Protter AA.

Circ Res. 2004 Mar 5;94(4):453-61. Epub 2004 Jan 15.

42.

Activation of p38 mitogen-activated protein kinase in spinal microglia is a critical link in inflammation-induced spinal pain processing.

Svensson CI, Marsala M, Westerlund A, Calcutt NA, Campana WM, Freshwater JD, Catalano R, Feng Y, Protter AA, Scott B, Yaksh TL.

J Neurochem. 2003 Sep;86(6):1534-44.

43.

Spinal p38 MAP kinase is necessary for NMDA-induced spinal PGE(2) release and thermal hyperalgesia.

Svensson CI, Hua XY, Protter AA, Powell HC, Yaksh TL.

Neuroreport. 2003 Jun 11;14(8):1153-7.

PMID:
12821799
44.
45.

B-type natriuretic peptide for the treatment of congestive heart failure.

Schreiner GF, Protter AA.

Curr Opin Pharmacol. 2002 Apr;2(2):142-7. Review.

PMID:
11950624
46.

Differential expression of cardiac ANP and BNP in a rabbit model of progressive left ventricular dysfunction.

Luchner A, Muders F, Dietl O, Friedrich E, Blumberg F, Protter AA, Riegger GA, Elsner D.

Cardiovasc Res. 2001 Aug 15;51(3):601-7.

PMID:
11476751
47.

Altered patterns of gene expression in response to myocardial infarction.

Stanton LW, Garrard LJ, Damm D, Garrick BL, Lam A, Kapoun AM, Zheng Q, Protter AA, Schreiner GF, White RT.

Circ Res. 2000 May 12;86(9):939-45.

49.

Coronary vasodilator effects of BNP: mechanisms of action in coronary conductance and resistance arteries.

Zellner C, Protter AA, Ko E, Pothireddy MR, DeMarco T, Hutchison SJ, Chou TM, Chatterjee K, Sudhir K.

Am J Physiol. 1999 Mar;276(3 Pt 2):H1049-57.

PMID:
10070091
50.

Pharmacokinetics and biological actions of subcutaneously administered human brain natriuretic peptide.

Clemens LE, Almirez RG, Baudouin KA, Mischak RP, Grossbard EB, Protter AA.

J Pharmacol Exp Ther. 1998 Oct;287(1):67-71.

Supplemental Content

Loading ...
Support Center